Go to deals
Healthcare

Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.

Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.

Dimainvest is a holding company owned by Umberto Di Maio, the controlling shareholder of Shedir Pharma Group.

Shedir Pharma Group manufactures and distributes nutraceuticals, cosmetics and medical devices. The company is headquartered in Piano di Sorrento, Italy.

Oaklins Italy’s parent company, Banca Akros, acted as the appointed broker for the collection of shares in the voluntary public tender offer for 11.9% of Shedir Pharma Group’s shares by Dimainvest.

Parties

Talk to the deal team

Giulio Greco

Managing Director
Milan, Italy
Oaklins Italy

Nicola Vulcano

Director
Milan, Italy
Oaklins Italy

Marco Valsecchi

Associate
Milan, Italy
Oaklins Italy

Rita Vizzi

Analyst
Milan, Italy
Oaklins Italy

Related deals

CustomerXPs Software (Clari5) has been acquired by Perfios Software Solutions
TMT

CustomerXPs Software (Clari5) has been acquired by Perfios Software Solutions

Bengaluru-based SaaS firm Perfios Software Solutions Private Ltd. has acquired 100% of the equity shares in the fraud-detection platform CustomerXPs Software Private Ltd. (Clari5) for an undisclosed amount, enhancing its anti-financial crime management suite for financial institutions.

Learn more
Afric Phar has been acquired by Pharma Capital
Healthcare

Afric Phar has been acquired by Pharma Capital

Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.

Learn more
Xiel Limited has been acquired by MIS Healthcare
Private Equity | Healthcare

Xiel Limited has been acquired by MIS Healthcare

MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.

Learn more